1. Venditti J M: Preclinical drug development: rationale and methods.Seminars in Oncology
8, 349 (1981).
2. Golding A, Venditti J M, MacDonald J S, Muggia F M, Henney J E and DeVita V T: Current results of the screening program at the division of cancer treatment, National Cancer Institute.Eur J Cancer
17, 129 (1981).
3. NCI planning to switch drug development emphasis from compound to human cancer oriented strategy.Cancer Lett
10, 1–3 (1984).
4. Shoemaker R H, Wolpert-DeFilippes M K, Kern D H, Lieber M M, Makuch R W, Melnick N R, Miller W T, Salmon S E, Simon R M, Venditti J M and Von Hoff D D: Application of a human tumor colony-forming assay to new drug screening.Cancer Res
45 2145 (1985).
5. Martin D S, Balis M E, Frei E, Goldin A, Heppner G H, Holland J F, Houghton J A, Houghton P J, Johnson R K, Mittelman A, Rustum Y, Sawyer R C, Schmid F A, Stolfi R L, Young C W: The role of murine tumor models in cancer treatment research. Presented at the Work Shop on Disease Oriented Antitumor Drug Discovery and Development, NCI, Bethesda, MD, U.S.A., 9–10 January (1985).